{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:37:39Z","timestamp":1790858259697,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.canlet.2010.10.018","type":"journal-article","created":{"date-parts":[[2010,11,13]],"date-time":"2010-11-13T09:27:15Z","timestamp":1289640435000},"page":"115-121","source":"Crossref","is-referenced-by-count":29,"title":["Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?"],"prefix":"10.1016","volume":"300","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2010.10.018_b0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.canlet.2010.10.018_b0010","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia-advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.canlet.2010.10.018_b0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR\u2013ABL oncogene","volume":"40","author":"Sattler","year":"2003","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.canlet.2010.10.018_b0020","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR\u2013ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.10.018_b0025","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.10.018_b0030","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.10.018_b0035","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamiv correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2010.10.018_b0040","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.10.018_b0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.canlet.2010.10.018_b0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3322\/caac.20004","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2010.10.018_b0055","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","article-title":"Adherence to therapy with oral antineoplastic agents","volume":"94","author":"Partridge","year":"2002","journal-title":"J. Nat. Cancer Inst."},{"key":"10.1016\/j.canlet.2010.10.018_b0060","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.canlet.2010.10.018_b0065","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1002\/1097-0142(19930515)71:10+<3441::AID-CNCR2820711751>3.0.CO;2-P","article-title":"Treatment compliance in childhood and adolescence","volume":"71","author":"Tebbi","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2010.10.018_b0070","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/pds.1259","article-title":"Assessing medication adherence from pharmacy records","volume":"15","author":"Steiner","year":"2006","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.canlet.2010.10.018_b0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/BF00280102","article-title":"Measurement of patient compliance and the interpretation of randomized clinical trials","volume":"41","author":"Vander Stichele","year":"1991","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.canlet.2010.10.018_b0080","series-title":"Compliance with Therapeutic Regimens","author":"Sackett","year":"1976"},{"key":"10.1016\/j.canlet.2010.10.018_b0085","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1532-5415.1982.tb05623.x","article-title":"Intentional prescription nonadherence (noncompliance) by the elderly","volume":"30","author":"Cooper","year":"1982","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.canlet.2010.10.018_b0090","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.153.16.1863","article-title":"Adherence to treatment and health outcomes","volume":"153","author":"Horwitz","year":"1993","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.canlet.2010.10.018_b0095","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.279.18.1458","article-title":"Persistence of use of lipid-lowering medications: a cross-national study","volume":"279","author":"Avorn","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2010.10.018_b0100","first-page":"592","article-title":"Overview of patient compliance with medication dosing: a literature review","volume":"6","author":"Greenberg","year":"1984","journal-title":"Clin. Ther."},{"key":"10.1016\/j.canlet.2010.10.018_b0105","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/bmj.39069.489757.55","article-title":"Oral chemotherapy safety practices at US cancer centres: questionnaire survey","volume":"34","author":"Weingart","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.canlet.2010.10.018_b0110","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2010.10.018_b0115","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1200\/jco.2006.24.18_suppl.6119","article-title":"Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients on imatinib","volume":"24","author":"Tsang","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2010.10.018_b0120","doi-asserted-by":"crossref","first-page":"6038","DOI":"10.1200\/jco.2006.24.18_suppl.6038","article-title":"Compliance and persistency with imatinib","volume":"24","author":"Feng","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2010.10.018_b0125","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1182\/blood.V110.11.4553.4553","article-title":"Cytogenetic response in relation to the adherence to treatment with imatinib mesylate: a case control study","volume":"110","author":"Doti","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.10.018_b0130","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood.V112.11.4267.4267","article-title":"Adherence to imatinib mesylate treatment: two years follow up","volume":"112","author":"Doti","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.10.018_b0135","first-page":"22","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukemia","volume":"49","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.canlet.2010.10.018_b0140","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.1182\/blood.V110.11.5159.5159","article-title":"Compliance with imatinib mesylate associated with lower health resource utilization and costs for patients with CML and GIST","volume":"110","author":"Halpern","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.10.018_b0145","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.10.018_b0150","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.canlet.2010.10.018_b0155","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood.V114.22.2209.2209","article-title":"Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia","volume":"114","author":"StCharles","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.10.018_b0160","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2010.10.018_b0165","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study","volume":"21","author":"Hahn","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2010.10.018_b0170","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1097\/MLR.0b013e31819a5acc","article-title":"Physician communication and patient adherence to treatment: a meta-analysis","volume":"47","author":"Haskard Zolnierek","year":"2009","journal-title":"Med. Care"},{"key":"10.1016\/j.canlet.2010.10.018_b0175","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/01.HYP.2.6.757","article-title":"Can simple clinical measurements detect patient noncompliance?","volume":"2","author":"Haynes","year":"1980","journal-title":"Hypertension"},{"key":"10.1016\/j.canlet.2010.10.018_b0180","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/00005650-199909000-00002","article-title":"Validation of patient reports, automated pharmacy records and pill count with electronic monitoring of adherence to antihypertensive therapy","volume":"37","author":"Choo","year":"1999","journal-title":"Med. Care"},{"key":"10.1016\/j.canlet.2010.10.018_b0185","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/clpt.1989.121","article-title":"Time to stop counting the tablets?","volume":"46","author":"Pullar","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2010.10.018_b0190","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/clpt.1989.122","article-title":"The natural history of medication compliance in a drug trial: limitations of pill counts","volume":"46","author":"Rudd","year":"1989","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2010.10.018_b0195","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2165\/00003088-199427030-00004","article-title":"Role of patient compliance in clinical pharmacokinetics. A review of recent research","volume":"27","author":"Urquhart","year":"1994","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.canlet.2010.10.018_b0200","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0022-3476(05)80256-2","article-title":"Therapeutic adherence to oral medication regimens by adolescents with cancer. Laboratory assessment","volume":"120","author":"Festa","year":"1992","journal-title":"J. Pediatr."},{"key":"10.1016\/j.canlet.2010.10.018_b0205","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2010.10.018_b0210","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.beha.2009.09.007","article-title":"Pharmacologic monitoring and determinants of intracytoplasmatic drug levels","volume":"22","author":"Mahon","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.canlet.2010.10.018_b0215","first-page":"e22","article-title":"Effect of medication dosing frequency on adherence in chronic diseases","volume":"15","author":"Saini","year":"2009","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.canlet.2010.10.018_b0220","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/1054773808316941","article-title":"Use of electronic monitoring in clinical nursing research","volume":"17","author":"Ailinger","year":"2008","journal-title":"Clin. Nurs. Res."},{"key":"10.1016\/j.canlet.2010.10.018_b0225","first-page":"13","article-title":"Patient\u2013physician communication: why and how","volume":"105","author":"Travaline","year":"2005","journal-title":"J. Am. Osteopath. Assoc."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383510005033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383510005033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T20:07:18Z","timestamp":1592078838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383510005033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0304383510005033"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2010.10.018","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}